Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Copanlisib produces promising results in relapsed/refractory follicular lymphoma

George Follows • 14 Jun 2017
ICML 2017
Follicular Lymphoma Copanlisib

George Follows, MA, PhD, MRCP, FRCPath from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK discusses the latest early-phase clinical trial data on copanlisib, presented at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Indolent relapsed/refractory lymphoma patients receiving copanlisib as part of the trial tolerated the treatment well, with fewer of the adverse events typically linked to PI3K inhibitors. Dr Follows explains the promising data and the implications of these findings.

More from George Follows

Five-year follow up of the UK CLL Forum ibrutinib data
3:58
Five-year follow up of the UK CLL Forum ibrutinib data
George Follows • 20 Sep 2019
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
1:21
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
George Follows • 2 May 2018
PEP-C for treatment of relapsed/refractory lymphoma
1:11
PEP-C for treatment of relapsed/refractory lymphoma
George Follows • 2 May 2018
MURANO study: exciting times in CLL
2:06
MURANO study: exciting times in CLL
George Follows • 9 Dec 2017

Related Videos

Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026
Changing community practice in FL: bispecific antibody delivery and treatment selection
2:44
Changing community practice in FL: bispecific antibody delivery and treatment selection
Kim Linton • 11 Sep 2026
Evolving treatment strategies at first relapse in follicular lymphoma
1:08
Evolving treatment strategies at first relapse in follicular lymphoma
Bradley Hunter • 21 Sep 2026
Selecting fixed-duration bispecific regimens in FL and DLBCL: treatment burden vs disease control
1:14
Selecting fixed-duration bispecific regimens in FL and DLBCL: treatment burden vs disease control
Pallawi Torka • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals